SEC Form 4 · accession 0001144204-17-021383

PLx Pharma Inc. · PLXP

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Operating Officer

Period of report

Apr 19, 2017

Accepted (ET)

Apr 20, 2017 · 9:17 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001497504

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Apr 19, 2017	A	70,982	—	A	70,982	D
Common Stock^F2	Apr 19, 2017	A	14,955	—	A	14,955	I	By Mossman Partners
Common Stock^F3	Apr 19, 2017	A	2,009	—	A	2,009	I	By spouse

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Options^F4,F5	$12.44	Apr 19, 2017	A	69,755	A	—	Jul 22, 2025	Common Stock	69,755	69,755	D

F1Received in exchange for 90,130 shares of common stock of PLx Opco Inc. (formerly PLx Pharma Inc.) in connection with the merger (the "Merger") of PLx Opco Inc. with a wholly owned subsidiary of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.).
F2Received in exchange for 18,989 shares of common stock of PLx Opco Inc. in connection with the Merger.
F3Received in exchange for 2,552 shares of common stock of PLx Opco Inc. in connection with the Merger. The Reporting Person disclaims beneficial ownership of these shares.
F4Received in connection with the Merger in exchange for an employee stock option to buy 88,571 shares of PLx Opco Inc. common stock for $9.80 per share.
F5The option is exercisable as to 51,754 shares as of the date hereof, and will become exercisable as to an additional 18,001 shares on July 22, 2017 (generally subject to continued employment or consulting relationship through such date).